The Rise of Incretin-based Therapies

Type 2 diabetes (T2D) remains a significant health concern globally, especially within the Indian population. Because the disease prevalence is rising, clinicians are focusing on therapies that address both insulin resistance and impaired secretion. Incretin-based therapies, including glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, have emerged as vital tools. These medications not only regulate glucose but also offer remarkable benefits for weight management. Consequently, they are now central to modern diabetes care strategies.

Clinical Benefits of Incretin-based Therapies

Modern research highlights that these agents offer more than just glycemic control. Additionally, they provide significant cardiovascular protection and facilitate substantial weight reduction. While the first GLP-1 receptor agonist was approved in 2005, the field has evolved rapidly. Today, clinicians can prescribe once-weekly injectables or daily oral formulations. Furthermore, dual agonists that target both GLP-1 and GIP receptors demonstrate superior metabolic outcomes compared to older treatments. As a result, patients at high cardiovascular risk can achieve better long-term health outcomes.

Managing Tolerability and Access

Despite their efficacy, these therapies frequently cause gastrointestinal side effects such as nausea or constipation. However, doctors can easily mitigate these issues through slow dose titration and comprehensive patient counseling. Encouraging smaller meals and proper hydration also helps improve patient adherence. Meanwhile, ongoing trials into triple-receptor agonists suggest even greater weight-loss potential in the future. Nevertheless, ensuring wider access to these advanced treatments remains a priority for healthcare systems.

Frequently Asked Questions

What are the primary advantages of dual GLP-1/GIP agonists?

Dual agonists provide enhanced glycemic control and more significant weight loss than single GLP-1 receptor agonists by utilizing synergistic hormonal pathways.

How should clinicians manage gastrointestinal side effects?

Gradual dose escalation over several weeks is the most effective strategy. Clinicians should also advise patients to eat smaller portions and avoid high-fat foods during drug initiation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Min E et al. Incretins for Type 2 Diabetes. Can J Physiol Pharmacol. 2026 Jun 06. doi: 10.1139/cjpp-2025-0142. PMID: 42250284.

Gao X et al. Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes. PubMed. 2026 Mar 23. doi: 10.1111/jdi.14231.

Refaeli R et al. Gastrointestinal side effects of incretin-based Obesity Management Medications. Int J Obes. 2025 Aug 28. doi: 10.1038/s41366-025-01887-2.